Providers usually consider the full picture
We are also finalizing as proposed (1) the flat benchmarks, as listed in Table 31 of the CY 2025 PFS proposed rule (89 FR 61861) and Table 34 of this final rule, for a non-inverse Medicare CQM, and (2) the flat benchmarks, as listed in Table 32 of the CY 2025 PFS proposed rule (89 FR 61862) and Table 35 of this final rule, for an inverse Medicare CQM under our final policy described in section IV.A.4.f.(1)(c)(i) of this final rule
Specifically, these articles warned about the hazadous downsides of pre-CHF administration of pimobendan: In "Comparative adverse cardiac effects of pimobendan and benazepril monotherapy in dogs with mild degenerative mitral valve disease: a prospective, controlled, blinded, and randomized study" , published in 2007 in the Journal of Veterinary Internal Medicine, the researchers found that "PIMO has adverse cardiac functional and morphologic effects in dogs with asymptomatic MVD." In "Increased Mitral Valve Regurgitation and Myocardial Hypertrophy in Two Dogs With Long-Term Pimobendan Therapy" , published in 2005 in Cardiovascular Toxicology, the researchers concluded "This is the first report to describe an increase in mitral regurgitation under clinical conditions in dogs treated with pimobendan
Gene set enrichment analysis (GSEA) confirmed that the chemokine receptors bind chemokines pathway was significantly upregulated in FADS-knockdown cells (Fig
